Insider Sale: CYRX Director Reduces Holdings to 26,275 Shares
Rhea-AI Filing Summary
Robert J. Hariri, a director of Cryoport, Inc. (CYRX), reported a sale of 5,000 shares of the company's common stock on 08/22/2025 at a reported price of $8.60 per share. Following this transaction he beneficially owned 26,275 shares, held directly. The Form 4 discloses only this non-derivative sale and contains no additional explanation.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director sold a modest portion of holdings; routine disclosure shows reduced direct ownership after a single open-market sale.
The reported sale of 5,000 shares at $8.60 reduces the director's direct stake to 26,275 shares. This filing is a standard Section 16 disclosure intended to inform investors of insider trading activity. No derivative transactions, option exercises, or 10b5-1 plan indicators are reported, and no explanatory remarks are provided.
TL;DR: Single-share sale reported; impact on capitalization is minimal based on disclosed quantities.
The transaction appears to be a simple disposition of common stock rather than a strategic corporate action. The sale amount and remaining ownership are explicitly stated. There is no information in the filing about motivations, larger pattern of trades, or changes to overall ownership structure, limiting inference about material market impact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,000 | $8.60 | $43K |
FAQ
What insider transaction did Cryoport (CYRX) report for Robert J. Hariri?
Does the Form 4 show any option exercises or derivative transactions for Hariri?
Is there any explanation provided for the sale in the Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.